Riggs Asset Management’s VanEck Biotech ETF BBH Stock Holding History

Riggs Asset Management’s Portfolio BBH Stock Details BBH Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q2	–	Sell	-71	Closed	-$9K	–	247
2020 Q1	$9K	Sell	71 -250	-78%	-$33.7K	0.01%	168
2019 Q4	$45K	Hold	321	–	–	0.02%	129
2019 Q3	$37K	Hold	321	–	–	0.02%	130
2019 Q2	$41K	Hold	321	–	–	0.02%	125
2019 Q1	$41K	Hold	321	–	–	0.03%	121
2018 Q4	$36K	Hold	321	–	–	0.03%	109
2018 Q3	$43K	Hold	321	–	–	0.02%	113
2018 Q2	$39K	Hold	321	–	–	0.02%	120
2018 Q1	$39K	Sell	321 -115	-26%	-$14.4K	0.02%	131
2017 Q4	$54K	Hold	436	–	–	0.02%	116
2017 Q3	$58K	Buy	436 +86	+25%	+$11.2K	0.03%	115
2017 Q2	$44K	Buy	+350	New	+$42.2K	0.02%	138

Other funds holding BBH

PAG

Pinnacle Advisory Group Columbia, Maryland $2.17B AUM 39.21% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Royal Bank of Canada Toronto, Ontario, Canada $570B AUM 27.57% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

MCM

Murphy Capital Management Bedminster, New Jersey $720M AUM 9.22% 1-Year Est. Return

LPL Financial San Diego, California $377B AUM 19.32% 1-Year Est. Return

MJRIC

Mogy Joel R Investment Counsel Beverly Hills, California $1.75B AUM 17.81% 1-Year Est. Return

Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return

Riggs Asset Management's BBH Position: Q2 2020 in Review

Riggs Asset Management sold out of VanEck Biotech ETF (BBH) in Q2 2020, closing a stake of 71 shares — an estimated $9K sold.

Riggs Asset Management first reported a position in BBH in Q2 2017 and held it in 12 quarters. The position peaked at $58K in Q3 2017. 102 funds tracked by Wall St. Rank hold BBH as of Q2 2020.

Riggs Asset Management reported no remaining VanEck Biotech ETF position as of Q2 2020 after selling out during the quarter.
Riggs Asset Management sold 71 VanEck Biotech ETF shares in Q2 2020, an estimated $9K.
Riggs Asset Management first reported a position in VanEck Biotech ETF in Q2 2017 and held it in 12 quarters.
Riggs Asset Management's VanEck Biotech ETF position peaked at $58K in Q3 2017.
102 funds tracked by Wall St. Rank held VanEck Biotech ETF as of Q2 2020.

Based on Riggs Asset Management's 13F filing for Q2 2020, filed 11 Aug 2020.